Of Cox's many picks, only CTIX has delivered the goods as far as clinical trial and pipeline progress. Many of us have been burned by NNVC, and it tarnishes CTIX to be mentioned in the same breath. Remember that the Mako article tried to do exactly that -- tried to blame Leo for NNVC's problems, when he left the company a decade ago on clearly acrimonious terms. (Remember he said he hadn't talked to them since, except for a couple of times he said hello when he encountered them at a conference.)

Anyway let's not turn this into the NNVC board. CTIX has made tremendously more progress in much less time., and I'm glad I took my losses on NNVC and put the remaining dough into CTIX.